May. 01, 2020 |
|
Feb. 26, 2021 |
|
jRCTs031200026 |
Multicenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia |
|
Combination therapy of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia |
Kyoji Moriya |
||
The University of Tokyo Hospital |
||
7-3-1, Hongo, Bunkyo-ku, Tokyo |
||
+81-3-3815-5411 |
||
moriya-tky@umin.org |
||
Mahoko Ikeda |
||
The University of Tokyo Hospital |
||
7-3-1, Hongo, Bunkyo-ku, Tokyo |
||
+81-3-3815-5411 |
||
mhk-ikeda@umin.ac.jp |
June. 11, 2020 |
||
160 | ||
Interventional |
||
randomized controlled trial |
||
single blind |
||
active control |
||
parallel assignment |
||
treatment purpose |
||
none |
||
1) Patients who have given written consent to participate in the study |
||
1) Patients with fever over 37.5 degrees for more than 10 days |
||
20age old over | ||
75age old not | ||
Both |
||
Coronavirus Disease 2019 (COVID-19) |
||
COVID-19 patients are randomly assigned to the group which adds Favipiravir and Nafamostat Mesilate to standard treatment or the group which add Favipiravir to standard treatment |
||
COVID-19 |
||
Change in patient condition on a 10-point scale from baseline to day7 |
||
1) Change in patient condition on a 10-point scale from baseline to day4 and day8 |
Recruiting |
The University of Tokyo foundation (COVID-19 Emergency Action Fund) | |
Not applicable |
Health Labour Sciences Research Grant | |
Not applicable |
The University of Tokyo, Clinical Research Review Board | |
7-3-1, Hongo, Bunkyo-ku, Tokyo | |
+81-3-5841-0818 |
|
ethics@m.u-tokyo.ac.jp | |
Approval | |
April. 30, 2020 |
No |
|